Effect of Pentoxifylline in Ameliorating Myocardial Injury in Patients With Myocardial Infarction Undergoing Thrombolytic Therapy: A Pilot Randomized Clinical Trial

Journal of Clinical Pharmacology
Hossein NamdarTaher Entezari-Maleki

Abstract

Cell death following acute myocardial infarction (MI) is the hallmark pathology of cardiovascular disease, leading to considerable mortality and morbidity. Platelet and neutrophil activation and inflammatory cytokines, prominently TNF-α, play an important role in the development of cell death. Because pentoxifylline inhibits platelet and neutrophil activation and reduces TNF-α, this study was performed to assess the potential benefit of pentoxifylline in the reduction of myocardial injury following acute MI. In this randomized clinical trial, 98 patients with acute MI were randomly divided into 2 groups. The intervention group received an oral dose of 1200 mg of pentoxifylline immediately before thrombolytic therapy (TLT). All patients received the same standard protocol for treatment of MI. Cardiac enzymes were checked over 48 hours. ST resolution was measured over 90 minutes. Then all patients were followed up for a 1-month period to assess major adverse cardiac effects (MACEs). There were no significant differences in peak levels of CPK (P = .18) and CK-MB (P = .33) between the 2 groups, whereas peak level of troponin I was significantly lower in the pentoxifylline group (16.8 ± 10.4 vs 21.3 ± 11.6; P = .048). No significant...Continue Reading

References

Sep 1, 1992·The Clinical Investigator·P LechleitnerH Tilg
Aug 1, 1995·Circulation·E FalkV Fuster
Apr 1, 1994·Journal of the American Academy of Dermatology·C P Samlaska, E A Winfield
Jan 1, 1995·Journal of Cardiovascular Pharmacology·X HouE Vicaut
Oct 31, 1996·The New England Journal of Medicine·E M OhmanE J Topol
Apr 20, 2001·The Annals of Thoracic Surgery·S C GaleP F McDonagh
Jul 27, 2001·Fundamental & Clinical Pharmacology·G SenerM Keyer-Uysal
Nov 13, 2001·American Journal of Physiology. Lung Cellular and Molecular Physiology·R T SchermulyD Walmrath
Mar 26, 2003·Journal of the American College of Cardiology·Stefan K JamesUNKNOWN GUSTO-IV-ACS Investigators
Dec 13, 2006·Journal of the American College of Cardiology·Henning SteenHugo A Katus
Jul 21, 2007·The Medical Clinics of North America·Véronique L Roger
May 8, 2010·European Heart Journal·Christophe A WyssWillibald Maier
Dec 23, 2011·Cell Death & Disease·M ChiongS Lavandero
Apr 23, 2015·European Heart Journal·Thomas F Lüscher

❮ Previous
Next ❯

Citations

Jun 3, 2020·Medical Hypotheses·Stelios F AssimakopoulosMarkos Marangos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.